AusBiotech

Biosceptre has announced an agreement with The University of Sydney and Children’s Medical Research Institute to establish a new research program on CAR-T cell immunotherapy.

Proteomics International Laboratories (ASX:PIQ) has announced it has signed a distribution licensing agreement for the immunoassay version of the PromarkerD predictive test for diabetic kidney disease.

Melbourne-based ASX-listed biotechnology company Amplia Therapeutics (ASX:ATX) will develop a potential new pancreatic cancer therapy discovered by scientists at the Cancer Therapeutics CRC.

Australian oncology-focused biotechnology company Kazia Therapeutics (ASX:KZA) has announced it has executed a definitive agreement with the Global Coalition for Adaptive Research to commence its participation in the GBM AGILE pivotal study in glioblastoma.

Australian company Specialised Therapeutics Australia has updated on a trial of its cancer therapy APLIDIN (plitidepsin) as a potential treatment for COVID-19 infection.

AusBiotech is seeking comment from affected members on two TGA consultations on medical devices: options for introducing a UDI system, and enhancing reporting of adverse effects.

Industry minister Karen Andrews has announced federal government backing for a Brisbane-based manufacturing facility that will produce products for clinical trials.

A new report has highlighted the potential benefits of diagnostics based on genome sequencing for the treatment of cancers but none have been recommended for funding and there is one over-ridng legal hurdle to their reimbursement in Australia.

Medical Developments International (ASX:MVP), the maker of the Penthrox (methoxyflurane) ‘green whistle’, has announced the appointment of Brent MacGregor as its new CEO.

"What a difference a year makes," said CSL chairman Brian MacNamee AO at the company's virtual annual general meeting.

A new cross-industry report has been released today, delivering a better understanding of the life sciences sector’s workforce needs and skills gaps.